跳至主要内容
临床试验/NCT03424525
NCT03424525已完成1 期

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human

University of Pennsylvania1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2018年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
16
试验地点
1
主要终点
Kinetics of uptake of [11C]TMP in human patients

研究概览

简要总结

Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will participate in two different imaging cohorts.

The Biodistribution cohort will include up to 5 patients referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.

The Dynamic cohort will include up to 25 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.

Patients will also undergo baseline lab tests complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and blood cultures. If these tests are done as part of clinical standard of care they will not need to be repeated for this study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria at least 18 years of age
  • Known or suspected bacterial infection.
  • Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

排除标准

  • Antibiotic therapy with trimethoprim within 48h of the baseline PET/CT scan.
  • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
  • Serious or unstable medical or psychological comorbidities that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
  • Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.

研究组 & 干预措施

Biodistribution

Experimental

The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.

干预措施: 11C-Trimethoprim (Drug)

Dynamic

Experimental

The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.

干预措施: 11C-Trimethoprim (Drug)

结局指标

主要结局

Kinetics of uptake of [11C]TMP in human patients

时间窗: 3 years

The biodistribution which includes kinetics of uptake of \[11C\]TMP in human patients via PET/CT will be measured

次要结局

  • The change in biodistribution which includes kinetics of uptake of [11C]TMP in human patients after therapy(3 years)
  • [11C]trimethoprim in infected versus non-infected tissues(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Mankoff

Principal Investigator

University of Pennsylvania

研究点 (1)

Loading locations...

相似试验